Advanced non-small cell lung cancer with KRAS G12C mutation

Clinical trials for Advanced non-small cell lung cancer with KRAS G12C mutation explained in plain language.

Never miss a new study

Get alerted when new Advanced non-small cell lung cancer with KRAS G12C mutation trials appear

Sign up with your email to follow new studies for Advanced non-small cell lung cancer with KRAS G12C mutation, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1

New drug combo aims to tackle tough lung cancer

Disease control Recruiting now

This early-stage trial is testing whether adding ladarixin to the standard drug sotorasib can help people with advanced KRAS G12C mutant non-small cell lung cancer. About 40 adults whose cancer has spread or cannot be removed will receive both pills daily. The study will first ch…

Matched conditions: ADVANCED NON-SMALL CELL LUNG CANCER WITH KRAS G12C MUTATION

Phase 1 • Sponsor: NYU Langone Health • Aim: Disease control

Last updated Jun 27, 2026 08:07 UTC

Advanced non-small cell lung cancer with KRAS G12C mutation

Get alerted when new Advanced non-small cell lung cancer with KRAS G12C mutation trials appear

New drug combo aims to tackle tough lung cancer